Key result
Current vitamin K antagonist exposure in newly diagnosed atrial fibrillation patients was associated with a stroke incidence of 0.9 per 100 patient-years compared to 3.4 during non-use.
Why the study?
What are the rates of vascular and bleeding outcomes requiring hospitalization in newly diagnosed atrial fibrillation patients stratified by vitamin K antagonist exposure?
Population
16,513 patients with a first diagnosis of atrial fibrillation between January 1, 2005, and February 28…
Comparison
Vitamin K antagonist exposure vs Non-use of vitamin K antagonists
Design
Cohort
Authors
Loading...
VKA use associated with lower stroke rates in new AF; extends observational data but leaves net benefit open pending RCTs.
Cohort (n=16,513)
What are the rates of vascular and bleeding outcomes requiring hospitalization in newly diagnosed atrial fibrillation patients stratified by vitamin K antagonist exposure?
Absolute Event Rate: 0.9% vs 3.4%
In a real-world UK cohort of newly diagnosed atrial fibrillation patients, current VKA use was associated with lower rates of stroke and myocardial infarction but higher rates of bleeding hospitalizations compared to non-use.
Gallagher et al. (2014) conducted a cohort in Atrial fibrillation (n=16,513). Vitamin K antagonist (VKA) exposure vs. Non-use, recent, and past exposure was evaluated on stroke. Current vitamin K antagonist exposure in newly diagnosed atrial fibrillation patients was associated with a stroke incidence of 0.9 per 100 patient-years compared to 3.4 during non-use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: